Overall survival (OS; upper panels) and progression-free survival (PFS; lower panels) in DLBCL patients.
- Ondrej Havranek (818835)
- Petra Kleiblova (752114)
- Jan Hojny (818836)
- Filip Lhota (818837)
- Pavel Soucek (57680)
- Marek Trneny (5665720)
- Zdenek Kleibl (752117)
Publication date
October 2015
DOIAbstract
<p>Panels show: <b>A.</b> the influence of all alterations affecting the CHK2 coding sequence (cds; HR<sub>OS</sub> = 2.3; 95% CI 0.77–6.97 and HR<sub>PFS</sub> = 2.6; 95% CI 0.91–7.44); <b>B.</b> the influence of the I157T mutation (HR<sub>OS</sub> = 2.9; 95% CI 0.70–12.00 and HR<sub>PFS</sub> = 5.2; 95% CI 1.25–22.16) and <b>C.</b> the influence of the c.319+43dupA variant (HR<sub>OS</sub> = 0.6; 95% CI 0.32–0.97 and HR<sub>PFS</sub> = 0.5; 95% CI 0.32–0.86).</p
Add to ORKG